GENFIT's G1090N Drug Candidate Shows Favorable Safety and Strong Anti-Inflammatory Activity
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Source: Globenewswire
- Clinical Trial Results: GENFIT's G1090N demonstrated a favorable safety and tolerability profile in Phase 1 trials, supporting further clinical evaluation and potentially offering new treatment options for acute liver failure patients.
- Anti-Inflammatory Activity: Ex vivo assays on peripheral blood mononuclear cells from healthy volunteers showed G1090N achieved up to 76% statistically significant inhibition of pro-inflammatory pathways, indicating its potential in treating acute liver failure.
- Next Steps: GENFIT plans to engage with regulatory authorities, including the U.S. FDA, to advance G1090N into Phase 2 proof-of-concept studies targeting ACLF, aiming to address significant unmet medical needs in this area.
- Market Outlook: The development of G1090N not only provides hope for acute liver failure patients but also positions GENFIT to solidify its leadership in liver disease, potentially driving future growth for the company.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like undefined with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
